Select publications

Baum M. The ATAC (Arimidex, Tamoxifen, Alone, or in Combination) adjuvant breast cancer trial in post-menopausal (PM) women. San Antonio Breast Cancer Symposium 2001;8. No abstract available

Baum M et al; ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002;359(9324):2131-9. Abstract

Baum M et al; The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98(9):1802-10. Abstract

Buzdar A, on behalf of the ATAC Trialists’ Group. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer — Updated efficacy results based on a median follow-up of 47 months. San Antonio Breast Cancer Symposium 2002;Abstract 13.

Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Winer EP et al. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptorpositive breast cancer: Status report 2004. J Clin Oncol 2005;23(3):619-29. Abstract

Cobleigh MA et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30(5 Suppl 16):117-24. Abstract

Dickler M et al. Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC). Proc ASCO 2004;Abstract 2001.

Gray R et al. The safety of adding angiogenesis inhibition into treatment for colorectal, breast, and lung cancer: The Eastern Cooperative Oncology Group’s (ECOG) experience with bevacizumab (anti-VEGF). Proc ASCO 2003;Abstract 825.

Hilan KJ et al. The role of VEGF expression in response to bevacizumab plus capecitabine in metastatic breast cancer (MBC). Proc ASCO 2003;Abstract 766.

Ignoffo RJ. Overview of bevacizumab: A new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm 2004;61(21 Suppl 5):21-6. Abstract

Miller KD. E2100: A phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 2003;3(6):421-2. No abstract available

Miller KD. Recent translational research: Antiangiogenic therapy for breast cancer – Where do we stand? Breast Cancer Res 2004;6(3):128-32. Abstract

Overmoyer B et al. Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer. Proc ASCO 2004;Abstract 727.

Rugo HS. Bevacizumab in the treatment of breast cancer: Rationale and current data. Oncologist 2004;9(Suppl 1):43-9. Abstract

Chebil G et al. Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer — Clinical associations and reasons for discrepancies. Acta Oncol 2003;42(7):719-25. Abstract

Diaz LK et al. Interobserver agreement for estrogen receptor immunohistochemical analysis in breast cancer: A comparison of manual and computer-assisted scoring methods. Ann Diagn Pathol 2004;8(1):23-7. Abstract

Diaz LK, Sneige N. Estrogen receptor analysis for breast cancer: Current issues and keys to increasing testing accuracy. Adv Anat Pathol 2005;12(1):10-9. Abstract

Elledge RM et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study. Int J Cancer 2000;89(2):111-7. Abstract

Fisher ER et al. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer 2005;103(1):164-73. Abstract

Harvey JM et al. Estrogen receptor status by immunohistochemistry is superior to the ligandbinding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17(5):1474-81. Abstract

Wells CA et al; European Working Group for Breast Screening Pathology. Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union — An inter-laboratory study. Virchows Arch 2004;445(2):119-28. Abstract